Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal March 16, 2020 – Posted in: Open Orphan (ORPH)

Positive results from FLU-v vaccine challenge study (FLU-v 004), the second Phase IIb study of FLU-v, which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group, have now been published in a peer review journal FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate The publication in ‘npj Vaccines’ reported that one dose of FLU-v induced statistically significant reduction in mild to moderate influenza disease (MMID) defined as detection…

Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission January 20, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist pharmaceutical services company which has a focus on orphan drugs, is pleased to announce that admission to trading on AIM and Euronext Growth of its existing ordinary share capital and the new ordinary shares to be issued as consideration in connection with the Merger, will commence at 8.00 a.m. today. Highlights: · Completion of merger between Open Orphan and hVIVO creating a European full pharma services company in a compelling…

Open Orphan #ORPH – Result of General Meeting January 6, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan is pleased to announce that at the Company’s General Meeting held earlier today in relation to the Company’s proposed merger with hVIVO plc and the Proposed Placing, all of the Resolutions put to the meeting were duly passed. The Board is excited by the growth potential of the Enlarged Group following completion of the merger and looks forward to updating Shareholders on the Company’s progress going forward. The Offer remains subject to fulfilment…

Open Orphan #ORPH – Recommended All-Equity Offer for hVIVO #HVO December 9, 2019 – Posted in: Open Orphan (ORPH)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISION IN RELATION TO HVIVO SHARES OR NEW OPEN ORPHAN SHARES EXCEPT ON THE BASIS OF THE INFORMATION IN THE OFFER DOCUMENT, WHICH IS PROPOSED TO BE PUBLISHED IN DUE COURSE 9…

Open Orphan #ORPH – Publication of positive FLU-v vaccine challenge study results in journal March 16, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH announces completion of the merger with hVIVO and re-admission January 20, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – Result of General Meeting January 6, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – Recommended All-Equity Offer for hVIVO #HVO December 9, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL